PB1921: A RANDOMIZED, DOUBLE‐BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA‐POSITIVE HR‐MDS (SELECT‐MDS‐1)

Authors :: DeZern, A.
Marconi, G.
Deeren, D.
Diez Campelo, M.
Lübbert, M.
Krishnamurthy, P.
Nagy, Z.
Basak, G.
Jonášová, A.
Morozova, E.
Geissler, K.
Ofran, Y.
Kelley, H.
Volkert, A.
Baker, K.
Kang‐Fortner, Q.
Hodgson, G.
Madigan, C.
Roth, D. A.
Kelly, M.
Source :: HemaSphere; 2022 Supplement 3, Vol. 6, p1800-1801, 2p
Publication Year :: 2022

Full Text Access

Tools